SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech - Technical Analysis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jibacoa who wrote (421)6/12/2002 10:52:42 PM
From: EepOpp  Read Replies (1) of 544
 
thanks. Now who to believe?

>Next, mark July 10th on your calendar! The FDA is expected to decide whether to approve Medimmune's FluMist. If FluMist receives FDA approval, the vaccine should be launched in the September/October timeframe, which appears achievable based on successful manufacturing ramp-up and pending progress with the FDA. If approved, FluMist will not only boost the value of Medimmune's shares, but the bottom-line as well, as sales for FluMist can reach the hundred of millions in the next several years.

tools.thestreet.com{C7A483E3-CF98-4808-B760-0977294624E8}&symb=medi&sid=7635&orig=1&timer=
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News